Home › Funds › Vestal Point Capital, LP › RAPP
Vestal Point Capital, LP position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
Vestal Point Capital, LP reported holding 730,000 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$30.4M, representing 0.71% of its reported portfolio and ranking #35 among its reported holdings. Vestal Point Capital, LP has disclosed RAPP holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's RAPP position evolved
Vestal Point Capital, LP first disclosed a stake in RAPP in Q3 2025 at 950,000 shares (US$28.2M). The position peaked in Q1 2026 at 1,436,229 shares, worth US$44.9M. Across 4 filings, Vestal Point Capital, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 730,000 shares valued at US$30.4M — a reduction of -706,229 shares quarter over quarter.. Notable position changes include a 29% increase in Q1 2026 (shares rose 33% over the following quarter), a 49% trim in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 950.00K | $28.21M | New |
| Q4 2025 | 1.11M | $33.68M | Add |
| Q1 2026 | 1.44M | $44.94M | Add |
| Q2 2026 | 730.00K | $30.42M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- ARCH Venture Management, LLC 3.73M sh · $155.38M · Q2 2026
- Cormorant Asset Management, LP 2.66M sh · $110.74M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- JOHNSON & JOHNSON 1.78M sh · $74.36M · Q2 2026
- BAKER BROS. ADVISORS LP 1.55M sh · $64.47M · Q2 2026
- TRV GP VI, LLC 969.22K sh · $40.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Siren, L.L.C. 641.47K sh · $26.73M · Q2 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held RAPP?
Vestal Point Capital, LP has disclosed RAPP holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Vestal Point Capital, LP's current position in RAPP?
As of Q2 2026, Vestal Point Capital, LP holds 730.00K shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $30.42M, representing 0.71% of its reported portfolio and ranking #35.
Has Vestal Point Capital, LP been buying or selling RAPP?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in RAPP. The position peaked in Q1 2026 at 1.44M shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.